Den Europæiske Union - dansk - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin - diabetes mellitus, type 2 - narkotika anvendt i diabetes - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - narkotika anvendt i diabetes - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure.  chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformin-hydrochlorid - diabetes mellitus, type 2 - narkotika anvendt i diabetes - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astra zeneca ab - saxagliptin, dapagliflozin propandiol monohydrat - diabetes mellitus, type 2; diabetes mellitus; nutritional and metabolic diseases; metabolic diseases; glucose metabolism disorders - narkotika anvendt i diabetes - qtern, fastdosis kombination af saxagliptin og dapagliflozin, er indiceret hos voksne i alderen 18 år og ældre med type 2-diabetes mellitus:at forbedre glykæmisk kontrol, når metformin og/eller sulphonylurea (su) og en af de monocomponents af qtern ikke giver tilstrækkelig glykæmisk kontrol,når du allerede er i behandling med den frie kombination af dapagliflozin og saxagliptin. (se afsnit 4. 2, 4. 4, 4. 5 og 5. 1) efter tilgængelige data på kombinationer undersøgt.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

boehringer ingelheim - empagliflozin, metformin - diabetes mellitus, type 2 - narkotika anvendt i diabetes - synjardy er indiceret hos voksne i alderen 18 år og ældre med type 2-diabetes som et supplement til kost og motion til forbedring af glykæmisk kontrol:patienter, der ikke er tilstrækkeligt kontrolleret på deres maksimalt tolereret dosis af metformin alene, patienter, der ikke er tilstrækkeligt kontrolleret med metformin i kombination med andre glukose-sænkende lægemidler, herunder insulin;hos patienter, der allerede behandles med en kombination af empagliflozin og metformin som særskilte tabletter.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novo nordisk a/s - liraglutide - diabetes mellitus, type 2 - narkotika anvendt i diabetes - victoza er indiceret til behandling af voksne, unge og børn i alderen 10 år og derover med utilstrækkeligt kontrolleret type 2-diabetes som et supplement til kost og exerciseas monoterapi når metformin anses for uhensigtsmæssig på grund af intolerance eller contraindicationsin tillæg til andre lægemidler til behandling af diabetes. for undersøgelsens resultater med hensyn til kombinationer, effekt på glykæmisk kontrol og hjerte-kar-hændelser, og de studerede populationer.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propandiolmonohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - narkotika anvendt i diabetes - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. i tillæg til andre lægemidler til behandling af type 2-diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propandiolmonohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - narkotika anvendt i diabetes - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. i tillæg til andre lægemidler til behandling af type 2-diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, type 2 - narkotika anvendt i diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, type 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgængelige data på forskellige kombinationer).